HOME PAGE
COMPANY PROFILE
SCIENCE
PIPELINES
PARTNERSHIP
NEWS
CAREERS
CONTACT US
中文
EN
菜单
HOME PAGE
COMPANY PROFILE
Company Introduction
Company History
Management Team
NEWS
Neurophth News
SCIENCE
Gene Therapy
R&D Platforms
CMC Platforms
PIPELINES
Pipeline
Leber’s Hereditary Optic Neuropathy
Autosomal Dominant Optic Atrophy
Optic Nerve Injury
Vascular Retinopathy
CAREERS
Employee development
Working at Neurophth
Compensation & Benefits
CONTACT US
PARTNERSHIP
中文
EN
NEWS
2021-01-28
Neurophth Therapeutics Further Expands Ocular Gene Therapy Expertise with Appointment of Qiutang Li, Ph.D., as Chief Scientific Officer
2021-01-20
Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy
2020-09-24
ODD | Neurophth Therapeutics’ Treatment of Leber’s Hereditary Optic Neuropathy (LHON) Gene Therapy (NR082) Was Granted Orphan Drug Designation by U.S. FDA, Ophthalmic Gene Therapy Ushered in an Outbreak Period
2020-05-11
Neurophth Announces Presentations at ASGCT and ARVO Annual Meetings
2020-04-09
China's First Gene therapy Company Neurophth Finished $18M series A Financing
上一页
1
2
3
4
5